Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791894 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01791894: Completed Phase 1 study, sponsored by Stanford University.
NCT01791894 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01791894, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01791894
The ClinicalTrials.gov registry entry for NCT01791894 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT01791894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01791894 about?
NCT01791894 is a clinical study titled "Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma". This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing
What is the current status of trial NCT01791894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2013-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01791894?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT01791894?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.